An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced thyroid cancer are refractory to radioactive iodine (RAI)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Targeted therapies in combination with RAI result in structural decrease of metastatic lesions in 33% to 63% of patients that successfully take up RAI after redifferentiation. The true efficacy of targeted therapies with RAI remains to be proven in clinical trials against the efficacy of targeted therapies without RAI or against multi-kinase inhibitors.
Two-thirds of patients with advanced thyroid cancer are refractory to radioactive iodine (RAI).
APA
Boucai L (2025). An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer.. Endocrinology and metabolism clinics of North America, 54(3), 419-431. https://doi.org/10.1016/j.ecl.2025.03.012
MLA
Boucai L. "An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer.." Endocrinology and metabolism clinics of North America, vol. 54, no. 3, 2025, pp. 419-431.
PMID
40716896
Abstract
Two-thirds of patients with advanced thyroid cancer are refractory to radioactive iodine (RAI). Inhibition of genetic drivers of thyroid cancer in the intracellular mitogen-activated protein kinase pathway, like BRAF, RAS, RET, and NTRK, results in increased expression of thyroid differentiation genes and the sodium-iodine symporter. Targeted therapies in combination with RAI result in structural decrease of metastatic lesions in 33% to 63% of patients that successfully take up RAI after redifferentiation. The true efficacy of targeted therapies with RAI remains to be proven in clinical trials against the efficacy of targeted therapies without RAI or against multi-kinase inhibitors.
MeSH Terms
Humans; Thyroid Neoplasms; Iodine Radioisotopes; Cell Differentiation; Molecular Targeted Therapy
같은 제1저자의 인용 많은 논문 (5)
- Thyroid Cancer: A Review.
- A Review of Thyroid Cancer-Reply.
- Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy.
- Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study.
- Letter to the Editor From Boucai and Tuttle: "BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-Associated Mortality Risk in Papillary Thyroid Cancer".